PCN3 POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT (EMEND) IN HIGHLY EMETOGENIC CISPLATINE-BASED CHEMOTHERAPY

MLA

T Souchet, et al. “Pcn3 Population-Based Budget Impact Model of Aprepitant (Emend) in Highly Emetogenic Cisplatine-Based Chemotherapy.” Value in Health, vol. 8, Nov. 2005, pp. A33–34. EBSCOhost, https://doi.org/10.1016/s1098-3015(10)67241-5.

APA

T Souchet, Y Briand, Robert Launois, K Le Lay, & C Francesconi. (2005). Pcn3 Population-Based Budget Impact Model of Aprepitant (Emend) in Highly Emetogenic Cisplatine-Based Chemotherapy. Value in Health, 8, A33–A34. https://doi.org/10.1016/s1098-3015(10)67241-5

Chicago

T Souchet, Y Briand, Robert Launois, K Le Lay, and C Francesconi. 2005. “Pcn3 Population-Based Budget Impact Model of Aprepitant (Emend) in Highly Emetogenic Cisplatine-Based Chemotherapy.” Value in Health 8 (November): A33–34. doi:10.1016/s1098-3015(10)67241-5.